FREQUENCY OF BUNDLE BRANCH BLOCK IN PATIENTS WITH REDUCED EJECTION FRACTION HEART FAILURE
Main Article Content
Keywords
Bundle branch block (Left and Right), Reduced Ejection Fraction Heart Failure
Abstract
Objective: To determine the frequency of bundle branch block (Left and Right) in patients with Reduced Ejection Fraction (Heart Failure) and association with hypertension, duration of heart failure and ischemic heart disease presenting to cardiology department of Hayatabad Medical College.
Methodology: After approval from the hospital ethical committee, a total of 176 patients were observed to determine the frequency of bundle branch block (Left and Right) in patients of Reduced Ejection Fraction Cardiac Failure presenting to cardiology department from January 2021 to June 2021. It was a cross-sectional study and the approach of consecutive non-probability sampling was applied to get data from the patients. After admission in ward these patient were investigated and ECG and ECHO was done.
Results: Among 176 patients, age wise distribution was analyzed. Among 176 patients as n= 30-40 Years 6 (3.4%), 41-50 Years 29 (16.5%), 51-60 Years 75(42.6%) 61-70 Years 66 (37.5%). The mean age was 56.95 years ± 1.176 SD. Gender wise distribution was n= 115(65.3%) were male and 61(34.7%) were females. Frequency of BBB in this study was 30.1%.Hypertension was present in 139(79.0%) and absent in 37(21.0%) and 114(64.8%) were Diabetics. History of ischemic heart disease was seen in 92(52.3%).117 patients (66.5%) had a left bundle branch block, while 59 patients (33.5%) had a right bundle branch block.
Conclusion: BBB is a strong and independent predictor of worse outcome measures in patients with HF and lower LVEF. BBB is an unfavorable prognostic marker .52% had history of ischemic heart disease and BBB onset within 3 months of heart failure and strong association with hypertension seen in 92% patients
References
2. American Heart Association. Classes of heart failure.
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHe artFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#.WUcGfvyuHs. Updated: May 8, 2017; Accessed: June 18, 2017.
3. Yancy CW, Jessup M, Bozkurt B, et al, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15. 128(16):e240-327.
4. Ponikowski P, Voors AA, Anker SD, et al, for the Authors/Task Force Members. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14. 37 (27):2129-200. [].
5. Lindenfeld J, Albert NM, Boehmer JP, et al, for the Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010 Jun. 16(6):e1-194.
6. Stiles S. FDA approves heart sympathetic activity imaging agent for HF evaluation. Medscape News from WebMD. March 22, 2013. Available at
http://www.medscape.com/viewarticle/781309. Accessed: April 5, 2013.
7. Braunwald E. The pathogenesis of congestive heart failure: then and now. Medicine. 1991 Jan. 70(1):68-79.
8. Greyson CR. Pathophysiology of right ventricular failure. Crit Care Med. 2008 Jan. 36 (1 suppl):S57-65.
9. Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008 Apr 1. 117(13):1717-31.
10. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009 Feb 17. 53 (7):557-73.
11. Kajstura J, Leri A, Finato N, Di Loreto C, Beltrami CA, Anversa P. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A. 1998 Jul 21. 95 (15):8801-5.
12. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. Circulation. 1995 May 15. 91 (10):2504-7.
13. Cody RJ. Hormonal alterations in heart failure. In: Hosenpud JB, Greenberg BH, eds. Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. Philadelphia, PA: Lippincott Williams & Wilkins; 2000. 199-212.
14. Anversa P, Nadal-Ginard B. Myocyte renewal and ventricular remodelling. Nature. 2002 Jan 10. 415 (6868):240-3.
15. Leri A, Claudio PP, Li Q, et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest. 1998 Apr 1. 101 (7):1326-42.
16. Kajstura J, Leri A, Castaldo C, Nadal-Ginard B, Anversa P. Myocyte growth in the failing heart. Surg Clin North Am. 2004 Feb. 84 (1):161-77.
17. Henes J, Rosenberger P. Systolic heart failure: diagnosis and therapy. Curr Opin Anaesthesiol. 2016 Feb. 29 (1):55-60.
18. Nicoara A, Jones-Haywood M. Diastolic heart failure: diagnosis and therapy. Curr Opin Anaesthesiol. 2016 Feb. 29 (1):61-7.
19. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000 Mar 1. 35 (3):537-44.
20. Gary R, Davis L. Diastolic heart failure. Heart Lung. 2008 Nov-Dec. 37 (6):405-16.
21. Morris DA, Gailani M, Vaz Perez A, et al. Right ventricular myocardial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. J Am Soc Echocardiogr. 2011 Aug. 24(8):886-97.
22. Jousilahti P, Harald K, Jula A, et al, for the National Institute for Health and Welfare-THL - Helsinki - Finland. Salt intake and the risk of heart failure [abstract 1192]. Presented at: European Society of Cardiology 2017 Congress; August 27, 2017; Barcelona, Spain. Eur Heart J. Aug 2017. 38 (suppl 1):240.
23. Davenport L. High salt intake linked to increased heart-failure risk. Medscape News from WebMD. August 28, 2017. Available at http://www.medscape.com/viewarticle/884824. Accessed: September 1, 2017.
24. Lam CS, Lyass A, Kraigher-Krainer E, et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation. 2011 Jul 5.124 (1):24-30.
25. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993 Jul. 88 (1):107-15.
26. Halley CM, Houghtaling PL, Khalil MK, Thomas JD, Jaber WA. Mortality rate in patients with diastolic dysfunction and normal systolic function. Arch Intern Med. 2011 Jun 27. 171 (12):1082-7.
27. Murphy RT, Starling RC. Genetics and cardiomyopathy: where are we now?. Cleve Clin J Med. 2005 Jun. 72 (6):465-6, 469-70, 472-3.
28. Benjamin EJ, Blaha MJ, Chiuve SE, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017 Mar 7. 135 (10):e146-
e603.
29. Ni H, Xu J. Recent trends in heart failure-related mortality: United States, 2000–2014. Centers for Disease Control and Prevention. December 31, 2015. Available at
http://www.cdc.gov/nchs/data/databriefs/db231.htm. Accessed: January 5, 2016
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Zahoor Ahmad Khan
Assistant Professor, Cardiac Electrophysiology Department, Hayatabad Medical Complex, Peshawar - Pakistan
Muhammad Arif
Resident, Cardiology Department, Hayatabad Medical Complex, Peshawar - Pakistan
Tariq Nawaz
Assistant Professor, Cardiology Department, Lady Reading Hospital, Peshawar - Pakistan